Review question / Objective: P: Adult patients of newly diagnosed and recurrent glioblastoma; I: Bevacizumab combined with conventional therapy; C: Conventional therapy; O: OS, PFS; S: RCT. Condition being studied: Glioblastoma is a kind of malignant solid tumors with poor prognosis. The standard treatment now is s u r g i c a l r e s e c t i o n c o m b i n e d w i t h radiotherapy and temozomide(TMZ). Since glioblastoma is hyperemic activation of VEGFA and HIF activation is upregulated, it

more »

... ht be a good candidate for antiangiogenesis treatment. And Bevacizumab (BEV) is a humanized monoclonal antibody against the VEGF ligand, which has showed favorable therapeutic effects on some solid Language: No limitations. Country(ies) involved: China.